Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data

Rivaroxaban (Bayer AG, Leverkusen, Germany) is a highly selective direct inhibitor of factor Xa. It has completed Phase III clinical trials evaluating its efficacy and safety against enoxaparin in the prophylaxis against venous thromboembolism (VTE) in orthopedic patients following primary total hip...

Descripción completa

Detalles Bibliográficos
Autor principal: Kwong, Louis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148419/
https://www.ncbi.nlm.nih.gov/pubmed/21822393
http://dx.doi.org/10.2147/VHRM.S4441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148419/
https://www.ncbi.nlm.nih.gov/pubmed/21822393
http://dx.doi.org/10.2147/VHRM.S4441

Ejemplares similares